Dexmedetomidine, an α2-adrenergic receptor agonist, shows promise in preventing postpartum depression, reducing symptoms and improving sleep and pain control in women with prenatal depression.
A history of hormonal contraception-associated depression may be associated with a higher risk for postpartum depression.
This register-based cohort study from Denmark of 503,158 clinically recognized pregnancies observed little or no risk of teratogenesis associated with first trimester exposure to antipsychotic medications.
Prenatal exposure to prescription stimulants was not associated with an increased risk of neurodevelopmental disorders in exposed children.
Vigilance is required in screening women who present with postpartum depression; a subset of women who screen positive for depression may actually have bipolar disorder.
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
A new study from Hantsoo and colleagues asks whether SRI treatment affects the levels of neuroactive steroids modulating GABA-A receptors.
Childbirth-related PTSD is relatively common; routine screening with a survey of PTSD symptoms may identify women in need of specific PTSD interventions.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In this multicenter cohort, maternal cannabis use documented using urine drug sampling was associated with increased risk of adverse pregnancy outcomes related to placental dysfunction.
